Because RA is a representative inflammatory disease and RA-FLSs exhibit p53 dysfunction and undergo a tumor-like EMT process, HRF/TCTP may potentially serve as a novel therapeutic target in the treatment of RA. This evidence concerns the gene TP53 and rheumatoid arthritis.